A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

An Observational Study on the Use of Nirsevimab for RSV Infection Prevention in Preterm Infants at a Single Center

  • By

  • Rina Su

  • Rigonggaowa A

  • Fang Yao

  • Yanbin An

  • Cheng Cai

  • Lei Yun

  • July 8, 2026

Share

  • 1

    The study evaluated nirsevimab's efficacy in preventing RSV infection in preterm infants at a single center from November 2024 to January 2026.

  • 2

    Nirsevimab immunized infants showed a significantly higher efficacy rate of 98.73% in preventing RSV infections compared to 84.81% in the non-immunized group.

  • 3

    In the non-immunized group, 15.18% of infants developed RSV infections, with some requiring respiratory support and experiencing adverse outcomes.

  • 4

    All RSV-infected infants in the non-immunized group required rehospitalization, averaging 15.5 days, while no rehospitalization occurred in the immunized group.

  • 5

    No significant adverse reactions were reported in the nirsevimab immunized group following the injection.

Original Source(s)

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants

  • by Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun

  • July 8, 2026

Related Content

FDA approves first therapy for warm autoimmune hemolytic anemia

The phase 2/3 ENERGY trial evaluated durable hemoglobin response with nipocalimab vs placebo in adults with warm autoimmune hemolytic anemia.

Correction: Electroacupuncture delays the progression of juvenile collagen-induced arthritis via regulation NLRP3/NF-κB signaling pathway -mediated pyroptosis and its influence on autophagy

A pretreatment multiphasic CT-based decision-support model for differentiating pediatric hepatoblastoma from focal nodular hyperplasia